Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience.
about
Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IXRecombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa.Acquired hemophilia A: emerging treatment options.Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues.International recommendations on the diagnosis and treatment of patients with acquired hemophilia ANew advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors.Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors.Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors.Factor VIII inhibitors: a 50-year perspective.Acquired hemophilia: a rare but life-threatening potential cause of bleeding in the intensive care unit.Parallel use of by-passing agents in haemophilia with inhibitors: a critical review.The literature on inhibitors: articles that influence my management of patients with hemophilia A and high-titer inhibitors.How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.How I manage patients with acquired haemophilia A.Sequential therapy with activated prothrombin complex concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience.A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors.Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitorsCase studies in the management of refractory bleeding in patients with haemophilia A and inhibitors.Monitoring rFVIIa 90 μg kg⁻¹ dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h.Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors.Major orthopaedic surgery for a haemophilia patient with inhibitors using a new bypassing agent.Major surgery in severe haemophilia A with inhibitors using a recombinant factor VIIa and activated prothrombin complex concentrate hybrid regimen.Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma.Evaluation of algorithms for the treatment of problem bleeding episodes in patients with hemophilia having inhibitors.Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors--phase I trial.How I treat inhibitors in haemophilia.Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents.Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study.A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.
P2860
Q33608230-4D12C694-0823-47B8-837B-0A9AE1FB1A45Q34548522-EAD435E8-82C6-4637-AFB0-AFB646C8C70CQ35605896-B9AC5B54-04E1-404D-87FD-9D1E1EEF02CBQ36981731-7F782BA2-4618-4F68-B46E-77A4BC85396DQ37146064-0B275B18-1327-4DC5-A96F-5F0A8C87C08EQ37169669-6624BE80-326A-4EC2-9A0E-47E731DB2E4AQ37185097-700B734E-B81E-4E48-9247-D0F66E3C59B6Q37609087-7F8A1E01-1218-4048-BCB5-CD5359C7C106Q37842692-B76E2D6B-3501-48A3-A406-97E1EEE84011Q37876956-173863C6-5219-484F-8503-C04C4EA08932Q37882559-FED791D3-0C53-4F33-9C46-E7969C040E9CQ37927122-654F31E0-20AD-4041-BE6E-25775CE7C391Q37999694-28389717-06E6-453A-B780-AA2C7A8855B8Q38060224-FDA78284-E4DE-4CE7-8FCE-28511B63E768Q38078394-B5E85ACD-8CDC-491C-B0BA-3992C8378755Q38182105-240CF47A-9A3B-40F1-BAD9-A6069B2FB7D9Q39169194-4C8557B6-E255-4D90-8074-8179B79AB421Q40539842-85169426-9D01-4C51-97DE-41EC56F6BAF4Q44211358-C25B5302-6B01-45E6-9EBB-8513DEFB5527Q44963707-598E4ABD-B88B-479E-94B9-7C2E6FF0075EQ45838031-3392A5E4-BD7A-41F5-9F89-81B3FB5FBCA4Q45851000-5158775F-B2BB-4F50-9178-E7F2B65943B7Q45856751-DD116538-59BF-453A-907D-70883F246831Q45862378-1A83058E-87AF-43A9-AE33-B52B4AD34E8DQ45867938-D1C8F526-4A81-426C-A4E0-4B06D919DC5FQ45869629-21EE577A-7057-4D2C-B7D6-E67CEBFC2FB2Q45869716-4710E8C1-C26D-46BD-9FE6-4F29FA3E89A7Q45879927-0AF5101A-8FE2-4963-81ED-9B2EA67CC5B6Q45886119-9DEDF7EE-F34B-417A-B770-2CF1592C330AQ45887437-856E72D1-6E6C-432B-81A6-0B01ADD7AD6FQ45888065-73E2F657-5457-48BB-BD98-6860E6C9BA91
P2860
Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Sequential therapy with activa ...... te of our previous experience.
@en
type
label
Sequential therapy with activa ...... te of our previous experience.
@en
prefLabel
Sequential therapy with activa ...... te of our previous experience.
@en
P2093
P2860
P1433
P1476
Sequential therapy with activa ...... te of our previous experience.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2516.2007.01451.X
P577
2007-05-01T00:00:00Z